New eczema drug shows promise in early trial
NCT ID NCT06723405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in skin severity over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trials New Zealand Ltd
Hamilton, 3204, New Zealand
-
Cornerstone Dermatology
Coorparoo, QLD 4151, Australia
-
Momentum Clinical Research Darlinghurst
Darlinghurst, NSW 2010, Australia
-
Momentum Clinical Research Dunedin
Dunedin, 9016, New Zealand
-
Momentum Clinical Research Kapiti
Paraparaumu, 5032, New Zealand
-
Momentum Clinical Research Lower Hutt
Hutt Central, 5010, New Zealand
-
Momentum Clinical Research Pukekohe
Pukekohe, 2120, New Zealand
-
Optimal Clinical Trials
Auckland, 1010, New Zealand
-
Optimal Clinical Trials North
Auckland, 0632, New Zealand
-
Pacific Clinical Research Network (PCRN) Auckland
Auckland, 0622, New Zealand
-
Pacific Clinical Research Network (PCRN) Christchurch
Christchurch, 8013, New Zealand
-
Pacific Clinical Research Network (PCRN) Tasman
Nelson, 7011, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.